Full Year 2024 Results Key Financial Results Revenue: US$388.5m (up 9.8% from FY 2023).

Medical device company Artivion (NYSE:AORT) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 3.9% year on ...

Artivion (NYSE:AORT – Get Free Report) had its target price reduced by equities research analysts at Stifel Nicolaus from $33 ...

Shares of medical device company Artivion (NYSE:AORT) fell 11.2% in the morning session after the company reported weak fourth-quarter 2024 results, as both revenue and EPS missed Wall Street's ...

Artivion, Inc. (NYSE:AORT – Get Free Report)’s stock price gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $27.85, ...

Needham lowered the firm’s price target on Artivion (AORT) to $32 from $34 and keeps a Buy rating on the shares after its Q4 results. The ...

The Kennesaw, Georgia-based company said it had a loss of 39 cents per share. Earnings, adjusted for one-time gains and costs, were less than 1 cent on a per-share basis. The biological medical device ...

In the latest quarter, 4 analysts provided ratings for Artivion AORT, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on ...

Artivion beat analysts’ revenue expectations by 0.5% last quarter, reporting revenues of $95.78 million, up 9% year on year. It was a very strong quarter for the company, with an impressive beat of ...

Booking Holdings and Mizuho Financial are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...

Stifel lowered the firm’s price target on Artivion (AORT) to $30 from $33 and keeps a Buy rating on the shares after Q4 consensus sales ...

Greetings, and welcome to the Artivion Fourth Quarter and Year End 2024 Financial Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure ...